The implementation of the Generating Antibiotic Incentives Now (GAIN) Act and other recent efforts to speed antibiotic development will only be successful if they encourage new chemical approaches that address the dearth of new chemical classes in the antibiotics pipeline. Antibiotic developers contacted by SciBX said solving bacteria-specific challenges will be addressed only by investing in new structure-guided synthesis and screening programs.